MedTrace Logo

Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

NCT00494767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-08-07

No results posted yet for this study

Summary

The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body. The body composition (fat,water, lean mass) is determined using a new investigational MR technology.

Conditions

  • Diabetes Mellitus, Type 2
  • Obesity

Interventions

DRUG

GW869682

GW869682 tablet with a dose strength of 250 mg will be available for subjects

DRUG

GSK189075

GSK189075 tablet with a dose strength of 250 mg will be available for subjects

DRUG

GSK189075-Placebo

Placebo tablets to match GSK189075 250 mg will be available for subjects

DRUG

GW869682-Placebo

Placebo tablets to match GW869682 250 mg will be available for subjects

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-29
Primary Completion
2007-06-07
Completion
2007-06-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00494767 on ClinicalTrials.gov